(HE) Preliminary pathology
Many patients with bone tumors will notify you that the pathology diagnosis also needs to be supplemented by immune group tests after the operation is done, and before the pathology report comes out. Many patients are very confused, didn't I pay the cost of pathology examination? Why do you have to do immunohistochemistry now, what is it for, and must it be done? If you have to do it, why didn't you do it together before?
Pathological picture (immunohistochemistry)
With this question, let's answer it to the majority of patients.
The so-called immunohistochemical test is short for immunohistochemical test. Definition is that the antigen binds specifically to the antibody, and the color of the tagged antibody is colored by a chemical reaction, thereby determining the antigens (peptides and proteins) within the tissue cell, and positioning, characterizing and quantifying them. Sounds very professional and complex, but in simple terms, immunohistochemistry can help us better diagnose the type and nature of tumors.
But does it have to be done? The answer is not yes. Because in the conventional tumor pathological diagnosis, about 10% of cases are difficult to make a definitive diagnosis by relying on basic HE staining alone. At this time, immunohistochemistry is needed to make the diagnosis accurate, especially in the differential diagnosis of lowly differentiated or undifferentiated tumors, with an accuracy rate of up to 75%. Therefore, not all patients need to do immunohistochemistry, but the pathologist will ask the patient to do immunohistochemistry and assist in the examination when faced with an unclear diagnosis.
At present, immunohistochemistry can bring us the following help in the diagnosis of bone tumors: (1) diagnosis and differential diagnosis of malignant tumors; (2) identification of the primary site of metastatic malignancy; (3) further pathological classification of a certain type of tumor; (4) the treatment of soft tissue tumors generally needs to be based on the correct histological classification, because of its variety, tissue morphology, sometimes it is difficult to distinguish its tissue source, the application of multiple markers for immunohistochemistry research is indispensable for the diagnosis of soft tissue tumors; (5) the discovery of tiny metastatic foci, Contributes to the determination of clinical treatment options, including the determination of the scope of surgery. (6) The choice of treatment plan for clinical provision.